ZG 2001
Alternative Names: ZG-2001Latest Information Update: 16 Jan 2024
At a glance
- Originator Suzhou Zelgen Biopharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors; SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 04 Dec 2023 Preclinical trials in Solid tumours in China (PO), prior to December 2023 (Suzhou Zelgen Biopharmaceuticals pipeline, December 2023)
- 10 Aug 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT06237413)
- 14 Feb 2023 National Medical Products Administration (NMPA) accepts regulatory application for ZG 2001